 "Cipla, Cipla logo, Cipla headquarters")
Drug major Cipla on Tuesday said it has launched a COVID-19 RT PCR testing kit in the country in partnership with diagnostics firm Genes2Me.
With the launch of the "RT-Direct multiplex COVID-19 RT PCR" test kit, the Mumbai-based drug firm is expanding its diagnostics offerings, it said in a regulatory filing.
Cipla will be responsible for the distribution of RT Direct kits in India and has commenced supply of the same, it added.
The kit is validated by the Indian Council of Medical Research (ICMR) and much more advanced than other RT PCR tests, the drug firm said.
RT-Direct test protocol does not require any RNA extraction process, making it faster and helping deliver results in just 45 minutes, it added.
It will also increase the throughput of any testing lab by threefold compared to the normal RT-PCR test protocol time of 120-150 minutes, Cipla noted.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
